{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-23-000016","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.764401+00:00","generated_at":"2026-06-16T11:29:50.721555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M","bullets":["GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).","VOXZOGO Q1 revenue $87.8M (+346% YoY); full-year guidance raised from $330-$380M to $380-$430M, driven by Japan and Brazil.","ROCTAVIAN full-year revenue guidance lowered to $50-$150M (from $100-$200M) due to Germany reimbursement shift and U.S. PDUFA delay to June 30, 2023.","Enzyme product revenues $448.1M (+5% YoY); ALDURAZYME up 41% on timing of orders to Sanofi.","Total cash & investments $1,492.7M; full-year revenue guidance unchanged at $2.375-$2.5B, with GAAP net income $155-$205M."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-23-000016","json":"https://secwatch.observer/filing/0001048477-23-000016.json","markdown":"https://secwatch.observer/filing/0001048477-23-000016.md","text":"https://secwatch.observer/filing/0001048477-23-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/0001048477-23-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/bmrn-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:29:50.721555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8f61614cfb5d2229c2e809a9023c4f46b01f762","claim":"BIOMARIN PHARMACEUTICAL INC updated its first quarter ended March 31, 2023 guidance (raised).","evidence_excerpt":"On April 26, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/0001048477-23-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}